Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.59 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.53 |
| ▸ | KLK7 | P49862 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 3/20 | 0.50 |
| ▸ | CTSS | P25774 | 4/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3276799 | 1.00 | SYK (0.59) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL1262680 | 1.00 | SYK (0.59) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL18976490 | 0.90 | SYK (0.57) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL31154007 | 0.90 | SYK (0.57) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL15928906 | 0.90 | ATM (0.62) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL17207697 | 0.90 | SYK (0.59) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL14119009 | 0.90 | ATM (0.62) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL6685926 | 0.90 | SYK (0.59) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL6685929 | 0.90 | SYK (0.59) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL5197783 | 0.90 | SYK (0.62) | SYKKLK5KLK7ATMPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196429-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-12 | — | — | WO | disclosed |
| CN-116601158-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-RE49594-E1 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2023-08-01 | — | — | US | disclosed |
| US-11535630-B2 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2022-12-27 | — | — | US | disclosed |
| CN-108602806-B | Improved apelin receptor (APJ) agonists and uses thereof | 研究三角协会 | 2022-07-12 | — | — | CN | disclosed |
| WO-2022076622-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| US-10954247-B2 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (NC) | 2021-03-23 | — | — | US | disclosed |
| US-20210070767-A1 | APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | RESEARCH TRIANGLE INSTITUTE | 2021-03-11 | — | — | US | disclosed |
| CN-105829286-B | Heteroaryl butanoic acid derivative as LTA4H inhibitor | 诺华股份有限公司 | 2019-05-31 | — | — | CN | disclosed |
| EP-3386976-A1 | IMPROVED APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | Research Triangle Institute, International (US) | 2018-10-17 | — | — | EP | disclosed |
| CN-1201454-A | Meta-guanidino, ureido, thioureido or azacyclic aminobenzoic acid derivatives as integrin antagonists | SEARLE & CO (US) | 1998-12-09 | — | — | CN | disclosed |
| EP-0715623-B1 | PLATELET AGGREGATION INHIBITORS | SEARLE & CO (US) | 1998-09-09 | — | — | EP | disclosed |
| EP-0850221-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1998-07-01 | — | — | EP | disclosed |
| WO-1997008145-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-03-06 | — | — | WO | disclosed |
| EP-0715623-A1 | PLATELET AGGREGATION INHIBITORS | G.D. SEARLE & CO. (US) | 1996-06-12 | — | — | EP | disclosed |
| US-5489594-A | ANTICOAGULANTS | G. D. SEARLE & CO. (US) | 1996-02-06 | — | — | US | disclosed |
| US-5441974-A | Phenyl amidines lactones useful as platelet aggregation inhibitors | G. D. SEARLE & CO. (US) | 1995-08-15 | — | — | US | disclosed |
| US-5430043-A | Platelet aggregation inhibitors | G. D. SEARLE & CO. (US) | 1995-07-04 | — | — | US | disclosed |
| WO-1995006038-A1 | PLATELET AGGREGATION INHIBITORS | G.D. SEARLE & CO. (US) | 1995-03-02 | — | — | WO | disclosed |
| WO-1993012103-A1 | PHENYL AMIDINES LACTONES USEFUL AS PLATELET AGGREGATION INHIBITORS | G.D. SEARLE & CO. (US) | 1993-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535630-B2 | Apelin receptor (APJ) agonists and uses thereof | APLNR, AP1G1, APMAP | SYK 4537/4885KLK5 2705/4885KLK7 1874/4885 |
| US-20210070767-A1 | APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | APLNR, AP1G1, APMAP | SYK 4537/4885KLK5 2705/4885KLK7 1874/4885 |
| US-10954247-B2 | Apelin receptor (APJ) agonists and uses thereof | APLNR, AP1G1, APMAP | SYK 4537/4885KLK5 2705/4885KLK7 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.